Amniotic fluid embolism: The complication of known pathomechanism but without pathogenetic therapy?

Thromb Haemost 2009; 101(05): 795-796
DOI: 10.1160/TH09-03-0160

Editorial Focus

Schattauer GmbH

Mieczyslaw Uszynski

¹Department of Propedeutics of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland

References
1 Zhou J, Liu S, Ma M. et al. Procoagulant activity and phosphatidylserine of amniotic fluid cells. Thromb Haemost 2009; 101: 845-851.
2 Clark SL, Hankins GDV, Dudley DA. et al. Amniotic fluid embolism: Analysis of the national registry. Am J Obstet Gynecol 1995; 172: 1158-1169.
3 Graeff H, Holzmann K, Gokel JM. et al. Pathomechanismen und Klinik der Fruchtwasserembolie. Geburtsh Frauenheilk 1978; 38: 887-894.
4 Hoffman M, Monroe IIIDM. A cell-based model of haemostasis. Thromb Haemost 2001; 85: 958-965.
5 Steiner PE, Lushbaugh CC. Maternal pulmonary embolism by amniotic fluid. J Am Med Assoc 1941; 117: 1245-1254.
6 Davies S. Amniotic fluid embolism and isolated disseminated intravascular coagulation. Can J Anesth 1999; 46: 456-459.
7 Gei A, Hankins GDV. Amniotic fluid embolism: an update. Contemporary Ob/Gyn 2000; 45: 53-64.
8 Stehr SN, Liebich I, Kamin G. et al. Closing the gap between decision and delivery – Amniotic fluid embolism with severe cardiopulmonary and haemostatic complications with a good outcome. Resistutation 2007; 74: 377-381.
9 Uszynski M. Heparin therapy in the primary phase of amniotic fluid embolism. Thromb Haemost 1984; 52: 362.